Eli Lilly (NYSE:LLY) said on Monday that its late-stage trial testing Jaypirca (pirtobrutinib), compared with chemoimmunotherapy, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, met its main goal.
The study showed an improvement in progression-free survival in patients treated with Jaypirca compared to those on chemoimmunotherapy, according to an independent review committee.
The overall survival, a secondary goal of the study, is not yet fully available, but early results suggest a strong benefit with Jaypirca. This will be formally evaluated in 2026, the company said.
The safety of Jaypirca in this study was generally similar to what has been seen in earlier trials, with no new concerns reported.